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Objective: Surgical treatment of native valve endocarditis remains challenging, especially in cases with para-
valvular destruction. Basic principles include complete debridement and reconstruction. This study is designed
to evaluate the outcomes of surgical reconstruction of complex annular endocarditis using standard techniques
and materials, including autologous and bovine pericardium.
Methods: From 1975 to 2000, 358 cases (357 patients, mean age 49  16 years, range 18–88 years) of native
valve endocarditis were surgically managed. Bioprosthetic valves were implanted in 189 cases, and mechanical
prostheses were implanted in 169 cases. A total of 78 cases of paravalvular destruction were identified: 62 annular
abscesses, 8 fistulas, and 8 combined abscesses/fistulas. These were managed with 46 pericardial patches and 32
isolated suture reconstructions after radical debridement and prosthetic valve replacement.
Results: The overall early mortality was 8.4% (n¼ 30). The mortality with paravalvular destruction was 17.9%,
and the mortality with simple leaflet infection was 5.7% (P ¼ .001). The unadjusted survival at 20 years was
26.4% 4.9% for bioprosthetic valves and 56.5% 8.1% for mechanical prostheses (P ¼ .007). The freedom
from recurrent prosthetic valve endocarditis was 78.9%  4.4% at 15 years. The freedom from reoperation for
recurrent prosthetic valve endocarditis was 85.8%  4.2% at 15 years. The freedom from reoperation after re-
construction for paravalvular destruction was 88.2%  6.9% at 15 years. The freedom from mortality for recur-
rent prosthetic valve endocarditis was 92.7% 3.4% at 15 years. The independent predictors of reoperation were
age (hazard ratio 0.930, P ¼ .005) and intravenous drug use/human immunodeficiency virus plus surgical tech-
nique (hazard ratio 12.8, P ¼ .003 for patch reconstruction plus valve and hazard ratio 3.6, P ¼ .038 for valve
replacement only). Prosthesis type was not predictive when separated from intravenous drug use/human immu-
nodeficiency virus (hazard ratio 3.268, P ¼ .088).
Conclusion: Paravalvular destruction is associated with a higher operative mortality. Native valve endocarditis
can be managed with reasonable long-term survival and low rates of reinfection with radical debridement and
pericardial reconstruction with bioprostheses and mechanical prostheses. The type of prosthesis implanted
does not influence long-term outcome. Patients with a history of intravenous drug use and human immunodefi-
ciency virus are at increased risk for recurrent infection and reoperation.Infectious endocarditis that does not resolve with appropriate
antibiotic therapy is a complicated problem associated with
substantial morbidity and mortality. Approximately one third
of patients with endocarditis will require operative interven-
tion.1-3 At least 10% of cases of endocarditis develop para-
valvular extension associated with the infection, which
adds significant morbidity and complexity to the surgery.4,5
The diagnosis of endocarditis requires a multifaceted
approach, including clinical, laboratory, and echocardio-
graphic data. The diagnosis of paravalvular extension is
imprecise. The presence of a new atrioventricular conduction
block suggests extension, as may persistent bacteremia, re-
current emboli, or a new pathologic murmur. The advent of
echocardiography has improved the quality of preoperative
evaluation, with the transesophageal approach being signifi-
cantly more specific and sensitive than the transthoracic im-
aging for defining extension and abscess.6,7 Color flow
Doppler techniques may demonstrate flow patterns consis-
tent with fistula formation, which is specific for extension.
Operative principles of endocarditis include complete de-
bridement of the infected tissues and drainage of abscess
cavities followed by restoration of anatomic relationships,
including ventriculo-aortic or atrioventricular continuity.
In the majority of cases the infection involves only the valve
leaflets; however, in cases with paravalvular destruction,
complex repair may be required to close acquired defects
and reverse hemodynamic abnormalities.
Multiple surgical options have been advanced for com-
plex reconstruction, and previously the literature has favored
From the University of British Columbia, Vancouver, Canada.
Presented to the Third Biennial Meeting of the Society for Heart Valve Disease
June 17–20, 2005.
Received for publication Sept 25, 2007; revisions received June 18, 2008; accepted for
publication Aug 7, 2008.
Address for reprints: W. R. Eric Jamieson, MD, 486 Burrard Bldg, St Paul’s Hospital,
1081 Burrard St, Vancouver, Canada V6Z 1Y6 (E-mail: eric.jamieson@ubc.ca).
J Thorac Cardiovasc Surg 2009;137:326-33
0022-5223/$36.00
Copyright  2009 by The American Association for Thoracic Surgery
doi:10.1016/j.jtcvs.2008.08.024
326 The Journal of Thoracic and Cardiovascular Surgery c February 2009
Fedoruk et al Acquired Cardiovascular Disease
A
C
DAbbreviations and Acronyms
AVR ¼ aortic valve replacement
BP ¼ bioprosthetic
HIV ¼ human immunodeficiency virus
HR ¼ hazard ratio
IVDU ¼ intravenous drug use
MP ¼ mechanical prosthesis
MVR ¼ mitral valve replacement
NVE ¼ native valve endocarditis
PVE ¼ prosthetic valve endocarditis
homograft reconstruction because of lower recurrent infec-
tion rates and the relative ease of complex repair.8-10 Unfor-
tunately, these grafts are not readily available, especially in
urgent and emergency settings.
The objective of this study is to examine the short- and
long-term outcomes of surgical reconstruction of complex
endocarditis using standard materials, including autologous
and bovine pericardium and mechanical and bioprosthetic
(BP) valves.
PATIENTS AND METHODS
A retrospective analysis of the prospectively maintained University of
British Columbia Cardiac Valve Database from 1975 to 2000 was con-
ducted to identify native valve endocarditis (NVE) cases. Follow-up was
conducted periodically through the years with telephone interviews, review
of consultative and echocardiographic documentation, and questionnaires to
primary care physicians. The University of British Columbia Cardiac Valve
Database receives annual renewal from the University of British Columbia
Clinical Research Ethics Board, which includes an informed consenting
process. A total of 358 cases of endocarditis managed surgically were iden-
tified in 357 patients. All operative notes were obtained and re-reviewed to
provide details of operative techniques. There were 257 men (72.0%) and
100 women (28.0%). The average age was 48.8  15.9 years (range 18–
88 years). The average age was 51.6  17.3 years for those with BP valves
and 45.6  13.5 years for those with mechanical prostheses (MPs) (P ¼
.0003, BP>MP). For the major portion of time interval from 1975 to
2000, valve repairs were not included in the University of British Columbia
Cardiac Valve Database; consequently, native valve repairs were not in-
cluded in the study.
Before the mid-1980s, endocarditis was diagnosed by classic clinical cri-
teria, including the combination of positive blood cultures, new or changed
murmur, fever, and the presence of progressive heart failure because echo-
cardiography was not available at our institutions before that time.11 More
recently, echocardiographic findings have been incorporated as a standard
mode for diagnosis. The definitive diagnosis was confirmed by surgical
identification of a vegetation or pathologic or bacteriologic diagnosis of
the vegetation. Abscess and fistula formation were diagnosed from the sur-
gical description in the operative note. An abscess was defined as a region of
necrosis with purulent material creating a cavity within the annulus or sur-
rounding paravalvular tissue in the setting of valvular infection. A fistula
was defined as an abnormal communication between 2 cardiac chambers.
If surgical reconstruction after extensive debridement was required, it
was defined as complex, requiring either primary suture repair or patch re-
construction using bovine or autologous pericardium. The type of valve
used was determined from the database. Follow-up was 96% complete.
The average follow-up length was 5.5  5.5 years. The follow-up was
The Journal of Thoracic and C6.1  6.1 years for BP and 4.9  4.5 years for MP (P ¼ .031 BP>
MP). Reinfection was defined as endocarditis of the prosthetic valve.
Given the large study time period and number of institutions with purged
medical records, the documentation of culture results was incomplete.
The details of the patient population are presented in Tables 1 and 2. The
distribution of BP (189) and MP (169) replacements by valve position are as
follows: 181 aortic valve replacements (AVRs) (BP 96, MP 85), 107 mitral
valve replacements (MVRs) (BP 58, MP 49), 8 tricuspid valve replacement
(BP 7, MP 1), and 62 MR (BP 28, MP 34). One patient had 1 MP-AVR and
1 MP-MVR at separate operations. The population included 78 cases (21%)
of paravalvular destruction. These included 70 cases of annular abscess or
abscess  fistula and 8 cases of chamber fistula. Table 2 identifies the rela-
tionship of abscesses/fistulas by valve position and type of prosthesis used
in the reconstruction procedure.
The follow-up of the patient population revealed that 18 patients under-
went reoperation for recurrent infection [prosthetic valve endocarditis
(PVE)] (Table 3). Of patients who had reoperation for PVE the mean age
was 35.2  11.6 years (61.1% were male and 38.9% were female). Of
the 18 patients, 12 involved AVR, 15 involved bioprostheses, and 10 had
a history of intravenous drug use (IVDU) or human immunodeficiency virus
(HIV). Of the 10 IVDU/HIV cases of recurrent PVE, 4 were initially recon-
structed by patch or suture repair and 6 valve replacements only (Table 1).
There were an additional 12 patients with recurrent infection who did not
have reoperation or were denied reoperation (Table 3).
Operative Technique
Patients were placed on cardiopulmonary bypass using standard cardiac
surgical techniques for the era. The basic surgical principle used was rad-
ical resection of all infected valvular and paravalvular tissue. If the infec-
tion was limited to the leaflets, simple resection and valve replacement
were used. If the infection had created a small annular abscess, this pocket
was often closed primarily with the horizontal mattress sutures that were
used to secure the valve prosthesis. The use of pledgets was dependent
on surgeon preference. If extension of the infection had occurred, radical
resection of all abscess cavities and adjoining structures was performed.
Patch reconstruction was then performed to restore anatomic continuity be-
tween adjoining structures. Either autologous pericardium or glutaralde-
hyde-fixed bovine pericardium was used. Fistulas were treated with
debridement and suture or patch closure as surgically indicated. The type
of valve implanted was based on surgeon preference, as well as standard
guidelines including age, anticoagulation risks, patient reliability, and pa-
tient preference. All patients were treated with antibiotics for a prolonged
period postoperatively.
Statistical Analysis
Values are expressed as the mean standard deviation unless otherwise
indicated. The Kaplan–Meier method was used to determine long-term sur-
vival and freedom from reoperation. Quantitative data were compared with
an independent samples t test. Comparisons of categoric variables were per-
formed with Fisher’s exact test (2 sided), Pearson’s chi-square test, or Yates
corrected chi-square test as appropriate. An independent statistician per-
formed the analysis.
The risk analysis, univariate and multivariate, was performed to identify
the independent predictors of recurrent infection and reoperation for recur-
rent infection. The risk variables considered were age, gender, valve posi-
tion, valve type, annular destructive disease, history or presence of IVDU
or HIV, and surgical reconstructive technique. Variables with a univariate
P value of less than .25 were evaluated in the multivariate modeling.
RESULTS
The overall operative mortality rate for NVE was 8.4%
(n ¼ 30). In the cohort with paravalvular destruction
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MVR, 4; MR, 5) compared with 5.7% (n ¼ 16) in patients
with simple leaflet infection (P ¼ .001). Ninety-eight
patients died during follow-up. The overall 10-year survival
was 58.2%  3.4%. Survival at 15 years was 36.6% 
4.4% for all patients, and this decreased to 32.6% 
4.8% by 20 years. The overall predictors of survival were
age (hazard ratio [HR] 1.030, P < .001), IVDU/HIV
(HR 3.22, P ¼ .00003), and patchþ valve reconstruction
(HR 2.90, P ¼ .0001).
PVE subsequently developed in 30 patients, with 18
(5.0%) managed with reoperation (Table 3). Of these 30
cases, 7 (23.3%) occurred in patients who had an abscess
or fistula at the time of the initial operation (Table 3). Oper-
ative mortality for reoperation was 16.6% (3 cases).
Of the 18 reoperative cases, abscess or fistula was present
at the initial operation in 3 cases. Of the 12 non-reoperative
cases, 8 died and 4 were alive at latest follow-up. Of the 8
deaths (AVR 6, MR 2), 3 AVR had abscess or fistula at
the initial operation. Of the 4 alive, non-reoperative cases
(AVR 1, MVR 2, MR 1), 1 MR had abscess at the initial
operation.
Overall freedom from recurrent infection was 85.8% 
3.0% at 10 years and 78.9%  4.4% at 15 years and 66.9
 8.7% at 20 years (Figure 1, A [30/358]). The freedom
TABLE 1. Patient population: Descriptive statistics
Variables Total 358 NO PVE reoperation n ¼ 340c YES PVE reoperation n ¼ 18 P value
Age (mean  SD) 357 49.53  15.73 35.18  11.64 .0001
Gender (male/female) 357 72.6% (246)/27.4% (93 patients) 61.1% (11)/38.9% (7) .291b
Valve position 0.479
AVR (181) 49.7% (169) 66.7% (12)
MVR (106) 30.3% (103) 16.7% (3)
TVR (8) 2.4% (8) 0% (0)
MR (63) 17.6% (60) 16.7% (3)
Valve type .015a
BP (189) 51.2% (174) 83.3% (15)
MP (169) 48.8% (166) 16.7% (3)
IVDU/HIV <.0001b
No (315) 90.3% (307) 44.4% (8)
Yes (43) 9.7% (33) 55.6% (10)
Disease .430
None (280) 77.9% (265) 83.3% (15)
Abscess  fistula (70) 20.0% (68) 11.1% (2)
Fistula only (8) 2.1% (7) 5.6% (1)
IVDU/HIVþ technique <.0001
IVDU/HIV: patchþvalve (8) 1.2% (4) 22.2% (4)
IVDU/HIV: sutureþvalve (1) 0.3% (1) 0% (0)
IVDU/HIV: valve only (34) 8.2% (28) 33.3% (6)
NO: patchþvalve (38) 11.2% (38) 0% (0)
NO: sutureþvalve (23) 6.5% (22) 5.6% (1)
NO: valve only (254) 72.6% (247) 38.9% (7)
Valve type in combination
IVDUþHIV
<.0001
1 BP: no IVDU or HIV (156) 44.1% (150) 33.3% (6)
2 MP: no IVDU or HIV (159) 46.2% (157) 11.1% (2)
3 BP: yes IVDU or HIV (33) 7.1% (24) 50.0% (9)
4 MP: yes IVDU or HIV (10) 2.6% (9) 5.6% (1)
Surgery technique .474
Patchþvalve (46) 12.4% (42) 22.2% (4)
Sutureþvalve (32) 6.8% (31) 5.6% (1)
Valve only (280) 80.9% (267) 72.2% (13)
PVE, Prosthetic valve endocarditis; SD, standard deviation; AVR, aortic valve replacement; MVR, mitral valve replacement; MR, multiple replacement; BP, bioprosthetic; MP,
mechanical prosthesis; TVR, tricuspid valve replacement; IVDU, intravenous drug use; HIV, human immunodeficiency virus. aYates corrected chi-square test. bFisher’s exact test,
2-tailed. cn ¼ 340 (inclusive of 12 with non-reoperative recurrent infection. No marker ¼ Pearson’s chi-square test.
TABLE 2. Location of abscess or fistula and type of valve implanted
Position Bioprosthetic valve Mechanical valve Total
Aortic 21 24 45
Mitral 13 8 21
Tricuspid 1 0 1
Multiple 1 10 11
Total 36 42 78
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(Figure 1, B). The freedom from recurrent PVE was not dif-
ferentiated by the presence or absence of annular destruction
(abscess  fistula) (P ¼ .132) (Figure 1, C). The freedom
from reoperation for patients with recurrent PVE was
91.7%  2.5% at 10 years, 85.8  4.2% at 15 years, and
72.8% 9.3% at 20 years (Figure 2). The 10-year freedom
from reoperation for annular destruction (abscess  fistula)
was 88.2% 6.9% and for pericardial patch reconstruction
was 71.5%  14.6%. There was 1 reoperation for isolated
suture repair of fistula at 209.5 months. The overall freedom
from mortality from recurrent PVE (9/30 events) was 95.7%
 1.5% at 10 years and 92.7%  3.4% at 15 and 20 years
(Figure 3). Of the 3 mortalities from recurrent operative
PVE, 1 died 60 days or less after reoperation and 2 died
more than 60 days after reoperation.
Some 51.2% of patients (189) had a BP valve placed. The
operative mortality for this group was 10.0% compared with
6.5% for patients who had mechanical valves (P< .001).
Patients who had a BP valve were older compared with those
with mechanical valves (51.6  17.3 years vs 45.6  13.4
years, P< .001). 66.0% of the BP valves were placed in
male patients (P< .001), and 83.3% of the reoperations
for reinfection occurred in the BP group. (P ¼ .015). The
10-year survival was 50.8%  4.4% for those with BP
valves and 69.9  5.0% for those with mechanical valves
(P ¼ .007). The adjusted survival, evaluated by cumulative
hazard at the mean of the covariate age, revealed a 10-year
survival of 51.1%  4.4% for those with BP valves and
71.9%  5.0% for those with mechanical valves. The pre-
dictors of bioprostheses mortality were age (HR 1.023, P ¼
.002), IVDU/HIV (HR 3.23, P ¼ .0004), abscess/abscess
and fistula (HR 2.21, P ¼ .010), and patch þ valve (HR
2.04, P ¼ .020). The predictors of mortality in those with
MPs were age (HR 1.054, P<.0001), multiple replacement
TABLE 3. Summary of recurrent prosthetic valve endocarditis
Patients with reoperation (n ¼ 18/30)
Initial operation
Position No. Abscess Fistula Mortality
AVR 12 2 1a 3a
MVR 3 0 0 0
MR 3 0 0 0
Patients with no reoperation (n ¼ 12/30)
Initial operation
Position No. Abscess Fistula Mortality
AVR 7 3b — 6b
MVR 2 — 0 0
MR 3 1c — 2c
AVR, Aortic valve replacement; MVR, mitral valve replacement; MR, multiple replace-
ment. aOne previous fistula at initial operation. bThree previous abscesses at initial op-
eration; all 3 died with recurrent PVE. cOne previous abscess at initial operation; alive
through follow-up.
The Journal of Thoracic and C(HR 3.87, P¼ .0005), and patchþvalve reconstruction (HR
2.98, P ¼ .007).
Forty-three patients (16.7%) in the overall cohort demon-
strated IVDU (40) or were HIV positive (3), and 10 of 43 pa-
tients (23.3%) were involved in 55.6% (10/18) of the
reinfections requiring reoperation. There were 46 repairs re-
quiring a pericardial patch overall. All 4 patch repairs that
ultimately required reoperation were in the IVDU/HIV
cohort.
The patient characteristics are presented in Table 1. The
univariate predictors for recurrent infection and reoperation
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FIGURE 1. A, Freedom from recurrent PVE (overall). B, Freedom from
recurrent PVE (prosthesis type). C, Freedom from recurrent PVE (paravalv-
ular destruction). BP, Bioprosthetic; MP, mechanical prosthesis.
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FIGURE 2. Freedom from reoperation for recurrent PVE (overall).
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FIGURE 3. Freedom from mortality for recurrent PVE.for recurrent infection are detailed in Tables 4 and 5. The
univariate predictors for reoperation for recurrent infection
are age (HR 0.93, P ¼ .001, protective), valve type BP>
MP (HR 4.77, P ¼ .015), IVDU/HIV (HR 11.63, P ¼
.000001), IVDU/HIV plus patch plus valve (HR 35.29,
P ¼ .00001), IVDU/HIV plus valve only (HR 7.56, P ¼
.001), and BP plus IVDU/HIV (HR 9.38, P ¼ .0001).
The independent predictors of recurrent PVE and recur-
rent PVE requiring reoperation are detailed in Tables 4
and 5. The univariate analysis detailed 5 significant predic-
tors in 18 patients. The independent predictors for recurrent
infection were: IVDU/HIVþ patchþ valve (HR 34.3, P<
.00003), IVDU/HIVþ sutureþ valve (HR 27.4, P ¼ .003)
and IVDU/HIVþvalve only (HR 5.87, P< .0001). The in-
dependent predictors of reoperation for recurrent PVE were
age (HR 0.93, P ¼ .005), IVDU/HIV plus patch plus valve
(HR 12.8, P ¼ .003), and IVDU/HIV plus valve only (HR
3.6, P ¼ .038). Valve type (BP>MP) was not predictive
for reinfection or reoperation (HR 3.29, P ¼ .088) by multi-
variate analysis. The independent predictors of recurrent in-
fection are not appreciably different from those for
reoperation for recurrent infection (Tables 4 and 5).
DISCUSSION
The incidence of infective endocarditis is between 1.7 and
6.2 cases per 100,000 person years and is at least 10 times
higher in patients with IVDU.12 The first line of therapy is
prolonged intravenous antibiotic therapy with a bactericidal
agent or agents. Often surgical referral occurs only after fail-
ure of the initial antibiotic therapy. The progressive infection
leads to significant valvular and paravalvular destruction
causing severe regurgitation and acute heart failure. It is
estimated that between 10% and 37% of patients have
some paravalvular complication at the time of surgery.4,13
Twenty-two percent of our cohort had paravalvular
involvement.
The surgical treatment of endocarditis is associated with
substantial morbidity and mortality. The spread of infection
from the valve leaflets to the surrounding tissue causes para-
valvular destruction, abscess formation, and fistulization.
These complications create a complex surgical problem. The
required debridement and subsequent restoration of anatomic
continuity can be surgically challenging. In the literature, para-
valvular infection is associated with a significantly increased
mortality and more frequent recurrent rates.5,13,14 However,
without surgery these patients have a poor outcome, with mor-
tality demonstrated at 100% in 1 study.15 Our study did not
demonstrate any increase in recurrence rates in patients with
documented paravalvular destruction versus those with only
leaflet involvement at 15years. However, notunlike other stud-
ies, there was a significant difference demonstrated in the oper-
ative mortality in patients with paravalvular destruction.
The principles of surgical treatment advocated by our
group for the treatment of active endocarditis with paravalv-
ular destruction are based on the premise of complete de-
bridement of the infected tissues and drainage of abscess
cavities followed by restoration of anatomic relationships,
including ventriculo-aortic or atrioventricular continuity.
The extensive defects that result from the complete resection
of all infected tissue require complex reconstruction in some
cases. Ultimately, we believe that the most important surgi-
cal principles are based on radical debridement to eradicate
the infection and provide acceptable long-term results. This
aggressive approach may be responsible for the improved
long-term outcomes seen in our study.
The use of homografts has been advocated as the treat-
ment of choice for multiple reasons.8,16,17,18 They have flex-
ibility and can be implanted to exclude abscess cavities.
Furthermore, the allograft often has a portion of the mitral
apparatus attached and provides a larger tissue area. There
is an intrinsic resistance to infection reported that is associ-
ated with a low rate of recurrent infection. Anticoagulation is
not needed as an adjunct after homograft implantation, and
therefore the related complications are avoided.
There are, however, several important issues related to
homograft use that make other surgical options attractive.
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DTABLE 4. Predictors for recurrent infection (univariate analysis and multivariate analyses)
Univariate Multivariate
Independent predictors Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Age 0.972 (0.948–0.998) .033 0.984 (0.955–1.015) 0.312
Gender
Male> female 1.351 (0.627–2.913) .442
Valve position .497
MVR 0.634 (0.234–1.715) .369
MR 1.612 (0.635–4.094) .315
Valve type
BP>MP 2.683 (1.083–6.644) .033 1.891 (0.673–5.313) 0.227
IVDU HIV drug user or HIV
Yes 13.135 (6.246–27.620) <.0001
Disease .334
Abscess  fistula 1.910 (0.760–4.796) .169
Fistula only 2.030 (0.271–15.191) .491
IVDUþHIVþTech <.0001
IVDU/HIV: patchþvalve 51.985 (17.913–150.865) <.0001 34.250 (10.674–109.899) <0.0001
IVDU/HIV: sutureþvalve 22.627 (2.838–180.392) .003 27.419 (3.030–248.154) 0.003
IVDU/HIV: valve only 7.394 (2.946–18.555) <.0001 5.869 (2.225–15.477) 0.0003
NO: patchþvalve — — 0.000 (0.000) 0.983
NO: sutureþvalve 0.719 (0.095–5.462) .749 0.689 (0.089–5.334) 0.721
NO: valve only (baseline) — — — —
Valve type in combination IVDUþHIV <.0001
MP: no IVDU or HIV 9.375 (3.061–28.712) .244
BP: yes IVDU or HIV 12.324 (05363–28.318) <.0001
MP: yes IVDU or HIV 5.401 (1.165–25.035) .031
Surgery technique .005
Patchþvalve 4.726 (1.850–12.072) .001
Sutureþvalve 1.052 (0.246–4.504) .945
CI, Confidence interval; MVR, mitral valve replacement;MR, multiple replacement; IVDU, intravenous drug use; HIV, human immunodeficiency virus; MP, mechanical prosthesis;
BP, bioprosthetic.Homografts have a rate of structural valve deterioration sim-
ilar to that of BP valves.19 They have limited availability in
many regions, including Canada. Reoperation on an in situ
homograft can be challenging.20
A recent study using homografts by Sabik and colleagues8
from the Cleveland Clinic demonstrated similar outcomes
despite significant differences in technique, when compared
with our results. The 10-year survival in their study was
56% compared with our overall 10-year survival of 58%,
and there were no differences in the 10-year freedom from
reoperation (96% vs 92%).
A significant proportion (16.7%) of our patient population
demonstrated IVDU or were HIV positive. These patients
were involved in 55.6% of the reoperations for reinfection
and all of the failed patch repairs that were initially performed
to repair abscesses or fistulas. This patient cohort challenges
available health care principles because of underlying socio-
economic and mental health issues. They often seek medical
attention late in the course of the disease process. This may
contribute to this cohort having more extensive infections at
initial presentation. Their immunocompromised state likely
The Journal of Thoracic and Ccontributes to this. Compliance with long-term antibiotic ther-
apy is poor, and they often continue to use intravenous drugs.
Some 73% of this cohort had a BP valve implanted, despite
being in general a younger patient group because of concerns
related to these factors.
Studies examining which valve is better for implantation
in light of endocarditis demonstrate equipoise. Moon and
colleagues21 found no difference in reinfection rates be-
tween BP and mechanical valves. Haydock and colleagues22
compared homografts with standard valves and found no ad-
vantage in either group. Lytle and colleagues24 at the Cleve-
land Clinic also found no difference in rates of reoperation or
survival among BP, mechanical, or homograft implanta-
tions. A study from the Texas Heart Institute demonstrated
an increase in reoperation rates for recurrent endocarditis
in patients with BP implantation.23
Our study demonstrated a significant increase in the rate
of reoperation for reinfection by univariate analysis in pa-
tients with a BP valve implanted. However, this difference
is negated using multivariate logistic regression. This is
most likely because of the common practice of implanting
ardiovascular Surgery c Volume 137, Number 2 331
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DTABLE 5. Predictors for reoperation for recurrent infection (univariate and multivariate analyses)
Univariate Multivariate
Independent predictors Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Age 0.927 (0.887–0.968) .001 0.930 (0.885–0.978) .005
Gender
Male> female 1.665 (0.627–4.424) .306
Valve position
MVR 0.410 (0.113–1.488) .175
MR 0.704 (0.192–2.581) .597
Valve type
BP>MP 4.770 (1.356–16.778) .015 3.268 (0.838–12.742) .088
IVDU HIV drug user or HIV
Yes 11.629 (0.4292–31.504) <.0001
Disease
Abscess  fistula 0.520 (0.116–2.327) .392
Fistula only 2.524 (0.291–21.860) .401
IVDUþHIVþTech .0002
IVDU/HIV: patchþvalve 35.286 (7.294–170.696) <.0001 12.832 (2.434–67.655) .003
IVDU/HIV: sutureþvalve — — — —
IVDU/HIV: valve only 7.561 (2.374–24.080) .001 3.632 (1.076–12.263) .038
NO: patchþvalve — — — —
NO: sutureþvalve 1.604 (0.189–13.635) .665 1.353 (0.144–12.743) .792
NO: valve only (baseline) — — — —
Valve type in combination IVDUþHIV <.0001
MP: no IVDU or HIV 0.318 (0.063–1.603) .165
BP: yes IVDU or HIV 9.375 (3.061–28.712) .0001
MP: yes IVDU or HIV 2.778 (0.301–25.609) .367
Surgery technique
Patchþvalve 2.015 (0.627–6.470) .239
Sutureþvalve 0.920 (0.115–7347) .937
CI, Confidence interval; MVR, mitral valve replacement;MR, multiple replacement; IVDU, intravenous drug use; HIV, human immunodeficiency virus; MP, mechanical prosthesis;
BP, bioprosthetic.BP valves in patients with a known history of IVDU and
HIV. This is not an unexpected finding given the known in-
crease risk that this patient population has for endocarditis.12
Our study did not demonstrate a difference in reinfection
rates between mechanical and BP valves in the general pop-
ulation using multivariate analysis.
All of the reoperations for reinfection with the patch clo-
sure technique for abscesses and fistulas occurred in patients
with IVDU. This suggests that the failures related to this
technique are significantly influenced by patient factors. Ini-
tial failure to seek attention and more extensive infection
processes are common in this group of patients. However,
these factors may also be surrogate markers for long-term
unreliability with respect to the requirement of prolonged
antibiotic therapy and risks of reinfection secondary to ongo-
ing intravenous use.
LIMITATIONS
There are limitations to this study. This evaluation is
a retrospective review extending over 25 years, and bio-
prostheses and MPs were used in a region where homo-
grafts were not readily accessible. The indications for
surgical interventions were based on classic criteria, but
acute and chronic phases were incompletely documented.
Given the large study time period and number of institu-
tions with purged medical records, the documentation of
culture results was incomplete. The exclusion of valve re-
construction/repair is a major limitation of the study. The
University of British Columbia Cardiac Valve Database
did not completely record valve reconstructions/repair pro-
cedures until 2000 when this study was completed. Regard-
less, given the historical nature of the study, mitral valve
repair was not used widely for the majority of the time
frame for this study.
CONCLUSIONS
Surgery for infective endocarditis is associated with high
morbidity and mortality. Patients are referred often only af-
ter they have developed significant and severe regurgitation
secondary to valvular and paravalvular destruction. This is
associated with a higher operative mortality rate. However,
despite the increased complexity of repair required for pa-
tients with paravalvular involvement, reasonable long-term
survival and low rates of reinfection can be obtained using
332 The Journal of Thoracic and Cardiovascular Surgery c February 2009
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Dstandard repair techniques if the principle of radical debride-
ment is followed. We demonstrated that standard techniques
are as reliable as reported results for homograft repairs. Pa-
tients with a history of IVDU and HIV are at increased risk
for reinfection and reoperation.
The authors extend appreciation to Kevin Shillitto and Florence
Chan for work in the preparation of the article.
References
1. Hill EE, Herijgers P, Herregods MC, Peetermans WE. Evolving trends in infec-
tive endocarditis. Clin Microbiol Infect. 2006;12:5-12.
2. Heiro M, Helenius H, Ma¨kila¨ S, Hohenthal U, Savunen T, Engblom E, et al. In-
fective endocarditis in a Finnish teaching hospital: a study on 326 episodes treated
during 1980-2004. Heart. 2006;92:1457-62.
3. Netzer ROM, Altwegg SC, Zollinger E, Ta¨uber M, Carrel T, Seiler C. Infective
endocarditis: determinants of long term outcome. Heart. 2002;88:61-6.
4. Anguera I, Miro JM, Evangelista A, Cabell CH, San Roman JA, Vilacosta I, et al.
Periannular complications in infective endocarditis involving native aortic valves.
Am J Cardiol. 2006;98:1254-60.
5. David TE, Regesta T, Gavra G, Armstrong S, Maganti MD. Surgical treat-
ment of paravalvular abscess: long-term results. Eur J Cardiothorac Surg.
2007;31:43-8.
6. Chambers HF. Transesophageal echocardiography in endocarditis. Chest.
94;105:333-4.
7. Jacob S, Tong AT. Role of echocardiography in the diagnosis and management of
infective endocarditis. Curr Opin Cardiol. 2002;17:478-85.
8. Sabik JF, Lytle BW, Blackstone EH, Marullo AGM, Pettersson GB,
Cosgrove DM. Aortic root replacement with cryopreserved allograft for prosthetic
valve endocarditis. Ann Thorac Surg. 2002;74:650-9.
9. Lytle BW, Sabik JF, Blackstone EH, Svensson LG, Pettersson GB,
Cosgrove DM 3rd. Reoperative cryopreserved root and ascending aorta replace-
ment for acute aortic prosthetic valve endocarditis. Ann Thorac Surg. 2002;74:
S1754-7.
10. Knosalla C, Weng Y, Yankah AC, Siniawski H, Hofmeister J,
Hammerschmidt R, et al. Surgical treatment of active infective aortic valve en-
docarditis with associated periannular abscess—11 year results. Eur Heart J.
2000;21:490-7.The Journal of Thoracic and C11. Nomenclature and Criteria for Diagnosis of Disease of the Heart and Great
Vessels, 8th edition. The Criteria Committee of the New York Heart Association.
Boston: Little Brown; 1979. p. 61.
12. Mylonakis E, Calderwood S. Infective endocarditis in adults. N Engl J Med. 2001;
345:1318.
13. Graupner C, Vilacosta I, San Roma’n JA, Ronderos R, Sarria C, Fernandez C, et al.
Periannular extension of infective endocarditis.JAmCollCardiol. 2002;39:1204-11.
14. Naqvi TZ, Boyatt J, Siegel RJ. Predictors of mortality in paravalvular abscess.
J Am Soc Echocardiogr. 2005;18:1404-8.
15. Lerakis S, Taylor WR, Lynch M, Litman CM, Clements SD, Thompson TD,
et al. The role of transesophageal echocardiography in the diagnosis and man-
agement of patients with aortic perivalvular abscesses. Am J Med Sci. 2001;
321:152-5.
16. Yankah AC, Pasic M, Klose H, Siniawski H, Weng Y, Hetzer R. Homograft
reconstruction of the aortic root for endocarditis with periannular abscess: a
17-year study. Eur J Cardiothorac Surg. 2005;28:69-75.
17. Vogt PR, von Segesser LK, Niederhauser U, Genoni M, Kunzli A, Schneider J,
et al. emergency surgery for acute infective aortic valve endocarditis: performance
of cryopreserved homografts and mode of failure. Eur J Cardiothorac Surg. 1997;
11:53-61.
18. Mahesh A, Angelini G, Caputo M, Jin XY, Bryan A. Prosthetic valve endocardi-
tis. Ann Thorac Surg. 2005;80:1151-8.
19. Lund O, Chandrasekaran V, Grocott-Mason R, Elwidaa H, Mazhar R,
Khaghani Z, et al. Primary aortic valve replacement with allografts over
twenty-five years: valve-related and procedure-related determinants of outcome.
J Thorac Cardiovasc Surg. 1999;117:77-91.
20. Kaya A, Schepens MA, Morshuis WJ, Heijmen RH, Brutel De La Riviere A,
Dossche KM. Valve-related events after aortic root replacement with cryopre-
served aortic homografts. Ann Thorac Surg. 2005;79:1491-5.
21. Moon MR, Miller DC, Moore KA, Oyer PE, Mitchell RS, Robbins RC, et al.
Treatment of endocarditis with valve replacement: the question of tissue versus
mechanical prosthesis. Ann Thorac Surg. 2001;71:1164-71.
22. Haydock D, Barratt-Boyes B, Macedo T, Kirklin JW, Blackstone E. Aortic valve
replacement for active infectious endocarditis in 108 patients. A comparison of
freehand allograft valves with mechanical prostheses and bioprostheses. J Thorac
Cardiovasc Surg. 1992;103:130-9.
23. Sweeney MS, Reul GJ, Cooley DA, Ott DA, Duncan JM, Frazier OH, et al. Com-
parison of bioprosthetic and mechanical valve replacement for active endocarditis.
J Thorac Cardiovasc Surg. 1985;90:676-80.
24. Lytle BW, Priest BP, Taylor PC, Loop FD, Sapp SK, Stewart RW, et al. Surgical
treatment of prosthetic valve endocarditis. J Thorac Cardiovasc Surg. 1996;111:
198-210.ardiovascular Surgery c Volume 137, Number 2 333
